Wise Guy
04-17-2009, 12:58 PM
Thanks to Datbtrue, as always, for this
Our peptide combo gets a solid mention in an editorial in the February issue of Nature Clinical Practice Endocrinology & Metabolism. I like the comparison of GHRH to GH therapy.
I like the mention of pulsatile GH secretion being superior as well.
Editorial Nature Clinical Practice Endocrinology & Metabolism (2009) 5, 123
Strategies to augment growth-hormone secretion in obesity by Steven Grinspoon
An alternative approach is to use agents that increase pulsatile secretion of GH and so address a fundamental abnormality of obesity. Administration of GHRH can reduce visceral fat, improve lipid profiles and increase adiponectin levels in patients with HIV and acquired visceral adiposity. Interestingly, GHRH specifically reduced visceral, rather than subcutaneous, fat in patients with lipodystrophy. Administration of either GH or GHRH to patients with lipodystrophy caused identical physiological increases in insulin-like growth factor I (IGF-I) levels; however, visceral fat was most reduced in the patients who received GHRH.
Moreover, 2 h blood-glucose levels increased in response to GH, but not GHRH, administration. Whether such differences reflect a physiologic effect of GHRH on endogenous pulsatile secretion of GH remains unclear. An additional advantage of GHRH is that feedback inhibition via IGF-I remains intact.
In contrast to GHRH, ghrelin and ghrelin-like peptides stimulate GH through the endogenous GH-secretagogue receptor, with some crosstalk to the GHRH receptor. These agonists can potentially increase GH secretion; however, they are not specific to GH, and could increase secretion of other pituitary hormones (e.g. cortisol). In addition, they are orexigenic.
Further investigation is necessary to determine whether GHRH and other GH secretagogues will prove useful to augment endogenous GH secretion, reduce visceral fat, and improve metabolic parameters in individuals with generalized obesity. Development of augmentation strategies that improve pulsatile GH secretion might uniquely target visceral fat, and so represent a novel approach to the treatment of obesity.
Our peptide combo gets a solid mention in an editorial in the February issue of Nature Clinical Practice Endocrinology & Metabolism. I like the comparison of GHRH to GH therapy.
I like the mention of pulsatile GH secretion being superior as well.
Editorial Nature Clinical Practice Endocrinology & Metabolism (2009) 5, 123
Strategies to augment growth-hormone secretion in obesity by Steven Grinspoon
An alternative approach is to use agents that increase pulsatile secretion of GH and so address a fundamental abnormality of obesity. Administration of GHRH can reduce visceral fat, improve lipid profiles and increase adiponectin levels in patients with HIV and acquired visceral adiposity. Interestingly, GHRH specifically reduced visceral, rather than subcutaneous, fat in patients with lipodystrophy. Administration of either GH or GHRH to patients with lipodystrophy caused identical physiological increases in insulin-like growth factor I (IGF-I) levels; however, visceral fat was most reduced in the patients who received GHRH.
Moreover, 2 h blood-glucose levels increased in response to GH, but not GHRH, administration. Whether such differences reflect a physiologic effect of GHRH on endogenous pulsatile secretion of GH remains unclear. An additional advantage of GHRH is that feedback inhibition via IGF-I remains intact.
In contrast to GHRH, ghrelin and ghrelin-like peptides stimulate GH through the endogenous GH-secretagogue receptor, with some crosstalk to the GHRH receptor. These agonists can potentially increase GH secretion; however, they are not specific to GH, and could increase secretion of other pituitary hormones (e.g. cortisol). In addition, they are orexigenic.
Further investigation is necessary to determine whether GHRH and other GH secretagogues will prove useful to augment endogenous GH secretion, reduce visceral fat, and improve metabolic parameters in individuals with generalized obesity. Development of augmentation strategies that improve pulsatile GH secretion might uniquely target visceral fat, and so represent a novel approach to the treatment of obesity.